Key result
The recalibrated Australian SCORE risk chart demonstrated good discrimination for 10-year CVD mortality (c-statistic 0.76 in men, 0.71 in women) and superior calibration compared to original models.
Why the study?
Does the recalibrated AusSCORE chart improve 10-year CVD mortality risk prediction compared to the original SCORE and Framingham equations in the Australian population?
Observational (n=1,998)
Yes
Does the recalibrated AusSCORE chart improve 10-year CVD mortality risk prediction compared to the original SCORE and Framingham equations in the Australian population?
Effect estimate: Harrell's c 0.76 (men) and 0.71 (women) (95% CI 0.69-0.84 (men), 0.62-0.80 (women))
The AusSCORE chart provides a valid and reliable tool for predicting 10-year CVD mortality risk in the general Australian population, outperforming original SCORE and Framingham equations.
May support recalibrated AusSCORE for Australian CVD risk assessment; extends SCORE validation but observational data leave practice change open.
BACKGROUND: Development of a validated risk prediction model for future cardiovascular disease (CVD) in Australians is a high priority for cardiovascular health strategies. DESIGN: Recalibration of the SCORE (Systematic COronary Risk Evaluation) risk chart based on Australian national mortality data and average major CVD risk factor levels. METHODS: Australian national mortality data (2003-2005) were used to estimate 10-year cumulative CVD mortality rates for people aged 40-74 years. Average age-specific and sex-specific levels of systolic blood pressure, total cholesterol and prevalence of current smoking were generated from data obtained in eight Australian large-scale population-based surveys undertaken from the late 1980s. The SCORE risk chart was then recalibrated by applying hazard ratios for 10-year CVD mortality obtained in the SCORE project. Discrimination and calibration of the recalibrated model was evaluated and compared with that of the original SCORE and Framingham equations in the Blue Mountains Eye Study in Australia using Harrell's c and Hosmer-Lemeshow chi statistics, respectively. RESULTS: An Australian risk prediction chart for CVD mortality was derived. Among 1998 Blue Mountains Eye Study participants aged 49-74 years with neither CVD nor diabetes at baseline, the Harrell's c statistics for the Australian risk prediction chart for CVD mortality were 0.76 (95% confidence interval: 0.69-0.84) and 0.71 (confidence interval: 0.62-0.80) in men and women, respectively. The corresponding Hosmer-Lemeshow chi statistics, the measure of calibration, were 2.32 (P = 0.68) and 7.43 (P = 0.11), which were superior to both the SCORE and Framingham equations. CONCLUSION: This new tool provides a valid and reliable method to predict risk of CVD mortality in the general Australian population.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2009) conducted an observational in Cardiovascular disease risk (n=1,998). Recalibrated SCORE risk chart vs. Original SCORE and Framingham equations was evaluated on 10-year CVD mortality prediction (discrimination and calibration) (Harrell's c 0.76 (men) and 0.71 (women), 95% CI 0.69-0.84 (men), 0.62-0.80 (women)). The recalibrated Australian SCORE risk chart demonstrated good discrimination for 10-year CVD mortality (c-statistic 0.76 in men, 0.71 in women) and superior calibration compared to original models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: